These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25641881)

  • 41. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
    Ansell SM
    Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT.
    Domingo-Domènech E; Boumendil A; Climent F; Sengeloev H; Wahlin B; Wattad W; Arat M; Finel H; Schapp N; Ganser A; Yeshurun M; Pavone V; Snowden J; Finke J; Montoto S; Sureda A; Dreger P;
    Bone Marrow Transplant; 2020 Apr; 55(4):796-803. PubMed ID: 31695174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.
    Tsirigotis P; Vassilakopoulos T; Batsis I; Bousiou Z; Gkirkas K; Sakellari I; Kaloyannidis P; Roussou P; Pangalis GA; Moschogiannis M; Vassilopoulos G; Repousis P; Megalakaki A; Michalis E; Kalpadakis C; Papadaki HA; Kotsianidis I; Hatzimichael E; Spyridonidis A; Anargyrou K; Poulakidas E; Giannoullia P; Apostolidis I; Stamouli M; Konstantopoulos K; Pappa V; Panayiotidis P; Harhalakis N; Anagnostopoulos A; Angelopoulou M
    Hematol Oncol; 2018 Oct; 36(4):645-650. PubMed ID: 29882363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.
    Ramsey SD; Nademanee A; Masszi T; Holowiecki J; Abidi M; Chen A; Stiff P; Viviani S; Sweetenham JW; Radford J; Zhu Y; Bonthapally V; Thomas E; Richhariya A; Hunder NN; Walewski J; Moskowitz CH
    Br J Haematol; 2016 Dec; 175(5):860-867. PubMed ID: 27649689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China.
    Liu J; Zheng L; Chuang LH
    J Med Econ; 2022; 25(1):99-107. PubMed ID: 34927526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
    Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
    Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
    Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
    Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
    Gautam A; Zhu Y; Ma E; Lee SY; Zagadailov E; Teasell J; Richhariya A; Bonthapally V; Huebner D
    Leuk Lymphoma; 2018 Jan; 59(1):69-76. PubMed ID: 28583027
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple successful desensitizations to brentuximab vedotin: a case report and literature review.
    DeVita MD; Evens AM; Rosen ST; Greenberger PA; Petrich AM
    J Natl Compr Canc Netw; 2014 Apr; 12(4):465-71. PubMed ID: 24717566
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
    Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
    Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of antibody-drug conjugate brentuximab vedotin in treating Hodgkin's lymphoma.
    Viviani S; Guidetti A
    Expert Opin Biol Ther; 2018 Aug; 18(8):841-849. PubMed ID: 29999431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
    Minich SS
    Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma.
    Lai CM; Horowitz S
    Expert Rev Hematol; 2013 Aug; 6(4):361-73. PubMed ID: 23991923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
    Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
    JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment of relapsed Hodgkin lymphoma after autologous stem cell transplantation].
    Illés Á; Simon Z; Udvardy M; Magyari F; Jóna Á; Miltényi Z
    Orv Hetil; 2017 Aug; 158(34):1338-1345. PubMed ID: 28823212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of Anaplastic Large Cell Lymphoma.
    Chihara D; Fanale MA
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):209-222. PubMed ID: 28340874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin].
    Arai H; Furuichi S; Nakamura Y; Nakamura Y; Ichikawa M; Mitani K
    Rinsho Ketsueki; 2016 May; 57(5):634-7. PubMed ID: 27263791
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.
    Parker C; Woods B; Eaton J; Ma E; Selby R; Benson E; Engstrom A; Sajosi P; Briggs A; Bonthapally V
    J Med Econ; 2017 Jan; 20(1):8-18. PubMed ID: 27472034
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful treatment of relapsed anaplastic large cell lymphoma with vinblastine monotherapy and allo-HSCT with reduced intensity conditioning regimen.
    Miyagaki S; Imamura T; Okumura Y; Ito I; Fujiki A; Osone S; Ishida H; Hosoi H
    Pediatr Int; 2015 Aug; 57(4):791-4. PubMed ID: 25847601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.